Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

504316 CP-55940 - CAS 83002-04-4 - Calbiochem

CP-55940 - CAS 83002-04-4 - Calbiochem MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: 5-(1,1-Dimethylheptyl)-2-[5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]phenol, CP 55,940, CP55940

Primary Target: CB receptors
504316
  
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

CAS #Empirical Formula
83002-04-4C₂₄H₄₀O₃
Description
Overview

This product has been discontinued.



A potent, non-selective agonist for cannabinoid (CB) receptors (Ki = 0.6 - 5.0 and 0.7 - 2.6 nM for CB1 and CB2 respectively; EC50 = 0.2, 0.3 and 5 nM for CB1, CB2 and GRP55 respectively). Often used in reference or control trials in CB research and the effects are robust in both behavioral tests and receptor binding assays.
Catalogue Number504316
Brand Family Calbiochem®
Synonyms5-(1,1-Dimethylheptyl)-2-[5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]phenol, CP 55,940, CP55940
References
ReferencesWiley, J., et al. 1995. Neuropharmacology. 34, 669.
Griffin, G., et al. 1998. J. Pharmacol. Exp. Ther. 285, 553.
Thomas, B., et al. 1998. J. Pharmacol. Exp. Ther. 285, 285.
Avdesh, A., et al. 2012. Psychopharmacology (Berl). 220, 405.
Product Information
CAS number83002-04-4
FormClear, colorless liquid
FormulationSupplied in methanol.
Hill FormulaC₂₄H₄₀O₃
Chemical formulaC₂₄H₄₀O₃
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary TargetCB receptors
Primary Target K<sub>i</sub>0.6 - 5.0 and 0.7 - 2.6 nM for CB₁ and CB₂ respectively.
Purity≥98% by HPLC
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
Toxicity Standard Handling
Storage -20°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
504316 0

Documentation

CP-55940 - CAS 83002-04-4 - Calbiochem SDS

Title

Safety Data Sheet (SDS) 

References

Reference overview
Wiley, J., et al. 1995. Neuropharmacology. 34, 669.
Griffin, G., et al. 1998. J. Pharmacol. Exp. Ther. 285, 553.
Thomas, B., et al. 1998. J. Pharmacol. Exp. Ther. 285, 285.
Avdesh, A., et al. 2012. Psychopharmacology (Berl). 220, 405.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision21-June-2013 JSW
Synonyms5-(1,1-Dimethylheptyl)-2-[5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]phenol, CP 55,940, CP55940
DescriptionA potent, non-selective agonist for cannabinoid (CB) receptors (Ki = 0.6 - 5.0 and 0.7 - 2.6 nM for CB1 and CB2 respectively; EC50 = 0.2, 0.3 and 5 nM for CB1, CB2 and GRP55 respectively). Often used in reference or control trials in CB research and the effects are robust in both behavioral tests and receptor binding assays.
FormClear, colorless liquid
FormulationSupplied in methanol.
CAS number83002-04-4
Chemical formulaC₂₄H₄₀O₃
Structure formulaStructure formula
Purity≥98% by HPLC
SolubilityDMSO (30 mg/ml)
Storage Protect from light
-20°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Standard Handling
ReferencesWiley, J., et al. 1995. Neuropharmacology. 34, 669.
Griffin, G., et al. 1998. J. Pharmacol. Exp. Ther. 285, 553.
Thomas, B., et al. 1998. J. Pharmacol. Exp. Ther. 285, 285.
Avdesh, A., et al. 2012. Psychopharmacology (Berl). 220, 405.